The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
 
Guillaume Grisay
No Relationships to Disclose
 
Fabio Turco
No Relationships to Disclose
 
Anna Patrikidou
Consulting or Advisory Role - Basilea
Travel, Accommodations, Expenses - Amgen Astellas BioPharma; Basilea Pharmaceutical; Janssen Oncology
 
Enrique Gallardo Díaz
No Relationships to Disclose
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Saskia Litiere
No Relationships to Disclose
 
Beatrice Fournier
No Relationships to Disclose
 
Silke Gillessen
Consulting or Advisory Role - AAA HealthCare (Inst); Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Europe GmbH (Inst); InnoMedica (Inst); Modra Pharmaceuticals (Inst); MSD Oncology; MSD Oncology (Inst); Myriad Genetics (Inst); Novartis (Inst); Orion (Inst); PeerVoice (Inst); Pfizer (Inst); Telix Pharmaceuticals (Inst); TOLREMO (Inst); WebMD/Medscape (Inst)
Speakers' Bureau - ASCO GU (Inst); ESMO; ESMO (Inst); German-speaking European School of Oncology (DESO); Silvia Grasso Consulting (Inst); Swiss Academy of Multidisciplinary Oncology (SAMO); Swiss Group for Clinical Cancer Research (SAKK); Swiss Group for Clinical Cancer Research (SAKK) (Inst)
Patents, Royalties, Other Intellectual Property - Method for biomarker (WO 3752009138392 A1)
Travel, Accommodations, Expenses - AstraZeneca; Bayer
Other Relationship - Cold Spring Harbor Laboratory (Inst); ProteoMediX
 
Bertrand F. Tombal
Honoraria - AAA/Endocyte/Novartis; Amgen; Astellas Pharma; AstraZeneca; Bayer; Ferring; Janssen; MSD Oncology; Myovant Sciences; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen; Myovant Sciences; Pfizer/Astellas; Sanofi; Steba Biotech; Takeda
Speakers' Bureau - Amgen; Astellas Pharma; Astellas Pharma; Janssen
Research Funding - Ferring (Inst)
Expert Testimony - Steba Biotech
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi